Suppr超能文献

蛋白二硫键异构酶抑制剂 3-甲基托巴因抑制基孔肯雅病毒。

The protein disulfide isomerase inhibitor 3-methyltoxoflavin inhibits Chikungunya virus.

机构信息

Collaborations Pharmaceuticals, Inc., 840, Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.

Sao Carlos Institute of Physics, University of Sao Paulo, Av. Joao Dagnone, 1100, Jardim Santa Angelina, Sao Carlos, SP 13563-120, Brazil.

出版信息

Bioorg Med Chem. 2023 Apr 1;83:117239. doi: 10.1016/j.bmc.2023.117239. Epub 2023 Mar 15.

Abstract

Chikungunya virus (CHIKV) is the etiological agent of chikungunya fever, a (re)emerging arbovirus infection, that causes severe and often persistent arthritis, as well as representing a serious health concern worldwide for which no antivirals are currently available. Despite efforts over the last decade to identify and optimize new inhibitors or to reposition existing drugs, no compound has progressed to clinical trials for CHIKV and current prophylaxis is based on vector control, which has shown limited success in containing the virus. Our efforts to rectify this situation were initiated by screening 36 compounds using a replicon system and ultimately identified the natural product derivative 3-methyltoxoflavin with activity against CHIKV using a cell-based assay (EC 200 nM, SI = 17 in Huh-7 cells). We have additionally screened 3-methyltoxoflavin against a panel of 17 viruses and showed that it only additionally demonstrated inhibition of the yellow fever virus (EC 370 nM, SI = 3.2 in Huh-7 cells). We have also showed that 3-methyltoxoflavin has excellent in vitro human and mouse microsomal metabolic stability, good solubility and high Caco-2 permeability and it is not likely to be a P-glycoprotein substrate. In summary, we demonstrate that 3-methyltoxoflavin has activity against CHIKV, good in vitro absorption, distribution, metabolism and excretion (ADME) properties as well as good calculated physicochemical properties and may represent a valuable starting point for future optimization to develop inhibitors for this and other related viruses.

摘要

基孔肯雅病毒(CHIKV)是基孔肯雅热的病原体,这是一种(重新)出现的虫媒病毒感染,会导致严重且经常持续的关节炎,同时也是全球范围内一个严重的健康问题,目前尚无抗病毒药物。尽管在过去十年中,人们努力寻找和优化新的抑制剂或重新定位现有的药物,但没有一种化合物能进展到 CHIKV 的临床试验,目前的预防措施基于病媒控制,但在控制病毒方面收效有限。我们努力纠正这种情况的工作始于使用复制子系统筛选 36 种化合物,最终使用基于细胞的测定法确定了天然产物衍生物 3-甲基呫吨酮具有抗 CHIKV 的活性(EC 200nM,在 Huh-7 细胞中的 SI=17)。我们还针对 17 种病毒对 3-甲基呫吨酮进行了筛选,结果表明它仅对黄热病毒(EC 370nM,在 Huh-7 细胞中的 SI=3.2)表现出抑制作用。我们还表明,3-甲基呫吨酮在体外具有良好的人源和鼠源微粒体代谢稳定性、良好的溶解度和高 Caco-2 渗透率,不太可能是 P-糖蛋白的底物。总之,我们证明 3-甲基呫吨酮对 CHIKV 具有活性,具有良好的体外吸收、分布、代谢和排泄(ADME)特性,以及良好的计算物理化学特性,可能代表了未来优化以开发针对这种病毒和其他相关病毒的抑制剂的有价值的起点。

相似文献

3
Chikungunya virus drug discovery: still a long way to go?基孔肯雅热病毒药物发现:任重而道远?
Expert Opin Drug Discov. 2019 Sep;14(9):855-866. doi: 10.1080/17460441.2019.1629413. Epub 2019 Jun 14.

本文引用的文献

1
5
Machine Learning Models for Activity: Prediction and Target Visualization.活动的机器学习模型:预测和目标可视化。
Mol Pharm. 2022 Feb 7;19(2):674-689. doi: 10.1021/acs.molpharmaceut.1c00791. Epub 2021 Dec 29.
6
Antivirals against the Chikungunya Virus.抗基孔肯雅病毒药物。
Viruses. 2021 Jul 5;13(7):1307. doi: 10.3390/v13071307.
10
Targeting Chikungunya Virus Replication by Benzoannulene Inhibitors.靶向基孔肯雅病毒复制的苯并薁抑制剂。
J Med Chem. 2021 Apr 22;64(8):4762-4786. doi: 10.1021/acs.jmedchem.0c02183. Epub 2021 Apr 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验